04:41 AM EDT, 09/13/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Immuneering ( IMRX ) shares rose more than 30% in premarket activity Friday after saying that a complete or partial response was observed in the first two patients with first-line pancreatic cancer getting IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in a phase 2a study.

The initial response rate in the trial was 40% while the initial disease control rate was 80%, the company said late Thursday in a statement.

All five patients in the study are continuing treatment after "positive initial response data," Immuneering ( IMRX ) said.

Additional patients were dosed with 320 milligrams once daily, and the drug is well tolerated in combination with gemcitabine/nab-paclitaxel, the company said.

Price: 1.87, Change: +0.44, Percent Change: +30.77